- Details
- Description
Packaging Size:
90 tablets
Strength:
50 mg
Composition:
Ripretinib 50 mg
Treatment:
Advanced gastrointestinal stromal tumor (GIST) in adults who have received 3 or more prior kinase inhibitors, including imatinib
Form:
Tablets
Brand:
LuciRip
Quantity Unit:
Tablets
Manufacturer:
Lucius Pharmaceuticals
LuciRip (Ripretinib) is a targeted anticancer medicine containing ripretinib, a tyrosine kinase switch-control inhibitor. It works by inhibiting KIT and PDGFRA signaling, which are important drivers of gastrointestinal stromal tumor (GIST) growth.
Ripretinib is used for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
LuciRip is an oral medication supplied as tablets and should be used under the supervision of a qualified healthcare professional according to the prescribed treatment plan.
